- Pfizer's COVID-19 RNA vaccine shows "robust" results in phase 1/2 trial published in Nature today. BNT162b1 "elicited a robust immune response in participants, which increased with dose level and with a second dose." https://www.nature.com/articles/s41586-020-2639-4 7 comments science
Linking pages
- Existing vaccines should work against new coronavirus variants—for now https://www.nationalgeographic.com/science/2021/01/existing-vaccines-should-work-against-new-coronavirus-variants-for-now/ 72 comments
- 🌈🐻 Pfizer $PFE Puts 🌈🐻 - Megabarbarian’s Newsletter https://megabarbar1an.substack.com/p/-pfizer-pfe-puts- 43 comments
- Why It’s a Big Deal If the First Covid Vaccine Is ‘Genetic’ | WIRED https://www.wired.com/story/why-its-a-big-deal-if-the-first-covid-vaccine-is-genetic/ 0 comments
- Here’s everything you need to know about Pfizer’s positive vaccine news | Ars Technica https://arstechnica.com/science/2020/11/heres-everything-to-know-about-pfizers-positive-vaccine-news/ 0 comments
- FDA devastation during the pandemic - a review https://moreisdifferent.blog/p/fda-devastation-during-the-pandemic 0 comments
Related searches:
Search whole site: site:www.nature.com
Search title: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults | Nature
See how to search.